Smith+Nephew sees further pandemic pain as annual profit slumps



© Reuters.

(Reuters) – Smith+Nephew warned on Thursday the impact of the COVID-19 pandemic is likely to continue into the first half of 2021 and that it was uncertain on the timing of recovery, as the medical products maker posted a drop in annual trading profit.

The British company, however, said it expects substantial underlying revenue growth in 2021, with its hip implants business outperforming knee implants, its sports medicine & ENT franchise performing strongly on market recovery and also forecasts better growth in its advanced wound-management business.

“We start 2021 with three clear priorities: to return to top-line growth and recapture momentum; to drive further operational improvement; and to continue to respond effectively to COVID-19,” Chief Executive Officer Roland Diggelmann said, adding that the company also expects 2021 profit margins to improve.

The company, a maker of orthopaedic implants and prosthetics, along with wound dressings and other surgical technologies, said trading profit slumped 42% to $683 million for the year ended Dec. 31, missing analyst estimates of $712 million.

Smith+Nephew said its fourth-quarter performance was hit by rising COVID-19 cases from mid-October, particularly in the United States and Europe, as hospitals and patients delayed elective surgeries.

 

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

READ  Hong Kong ETF Turnover Soars to Five-Year High as Crisis Deepens

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.





READ SOURCE

LEAVE A REPLY

Please enter your comment!
Please enter your name here